NETO2 and glioblastoma: Therefore, the combination of small molecule drugs targeting potential TAMs targets sLRIG3 and NETO2 with current immunotherapy such as ICBs, therapeutic vaccines, and traditional chemotherapy may be a promising strategy to improve the overall survival of GBM patients.